Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Compared with patients with 25(OH)D levels <15 ng/mL, those with levels of 15 to 25 ng/mL and >25 ng/mL exhibited greater reductions in HbA1c [β = −0.083, 95% CI (−0.154 to −0.013), p = 0.020; and β = −0.096, 95% CI (−0.173 to −0.017), p = 0.016, respectively] and BMI [β = −1.02, 95% CI (−1.46 to −0.58); and β = −1.29, 95% CI (−1.77 to −0.80); both p < 0.0001].

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We conducted a retrospective cohort study of 5,384 adults with T2D, enrolled in Leumit Health Services, who initiated semaglutide therapy between February 1, 2019, and December 31, 2022.

Source: Abstract.

Only patients aged ≥18 years with a definite diagnosis of T2DM (recorded in the diabetes mellitus registry) were included in the study.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Baseline vitamin D status is associated with glycemic and weight loss outcomes in patients with type 2 diabetes treated with semaglutide

Cohort study · Frontiers in Nutrition · 2026

Original publication title

Baseline vitamin D status is associated with glycemic and weight loss outcomes in patients with type 2 diabetes treated with semaglutide

Ariel Israel; Mahmud Moed; Hala Abo Fanne; Aviv Kedem; Mahmoud Odeh; Kareem Abu Rashed; Tayser Marzook; Isis Abumouch; Rami Abu Fanne

Copyright © 2026 Israel, Moed, Abo Fanne, Kedem, Odeh, Rashed, Marzook, Abumouch and Fanne.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Higher baseline 25(OH)D levels are independently associated with improved glycemic and weight loss responses to semaglutide in individuals with T2D. Prospective trials are warranted to explore whether vitamin D supplementation may potentiate semaglutide’s metabolic effects.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Semaglutide, a glucagon-like peptide-1 receptor agonist, is an established therapy for type 2 diabetes (T2D), offering robust glycemic control and weight reduction. Vitamin D has been implicated in metabolic regulation, yet its influence on semaglutide-induced outcomes remains unclear.

Source: Objective

Abstract: Research design and methods

We conducted a retrospective cohort study of 5,384 adults with T2D, enrolled in Leumit Health Services, who initiated semaglutide therapy between February 1, 2019, and December 31, 2022. All patients had documented serum 25-hydroxyvitamin D [25(OH)D] levels prior to treatment initiation. Metabolic outcomes: including glycemic control (HbA1c), body mass index (BMI), and lipid profile: were assessed at 12 months. Associations between baseline 25(OH)D levels and metabolic changes were evaluated using multivariable regression models, adjusted for demographic and clinical covariates.

Source: Research design and methods

Abstract: Results

The median baseline 25(OH)D level was 19.3 ng/mL. Compared with patients with 25(OH)D levels <15 ng/mL, those with levels of 15 to 25 ng/mL and >25 ng/mL exhibited greater reductions in HbA1c [β = −0.083, 95% CI (−0.154 to −0.013), p = 0.020; and β = −0.096, 95% CI (−0.173 to −0.017), p = 0.016, respectively] and BMI [β = −1.02, 95% CI (−1.46 to −0.58); and β = −1.29, 95% CI (−1.77 to −0.80); both p < 0.0001]. No association was found with lipid profile.

Source: Results

Abstract: Conclusion

Higher baseline 25(OH)D levels are independently associated with improved glycemic and weight loss responses to semaglutide in individuals with T2D. Prospective trials are warranted to explore whether vitamin D supplementation may potentiate semaglutide’s metabolic effects.

Source: Conclusion
Authors’ abstract

Objective

Semaglutide, a glucagon-like peptide-1 receptor agonist, is an established therapy for type 2 diabetes (T2D), offering robust glycemic control and weight reduction. Vitamin D has been implicated in metabolic regulation, yet its influence on semaglutide-induced outcomes remains unclear.

Research design and methods

We conducted a retrospective cohort study of 5,384 adults with T2D, enrolled in Leumit Health Services, who initiated semaglutide therapy between February 1, 2019, and December 31, 2022. All patients had documented serum 25-hydroxyvitamin D [25(OH)D] levels prior to treatment initiation. Metabolic outcomes: including glycemic control (HbA1c), body mass index (BMI), and lipid profile: were assessed at 12 months. Associations between baseline 25(OH)D levels and metabolic changes were evaluated using multivariable regression models, adjusted for demographic and clinical covariates.

Results

The median baseline 25(OH)D level was 19.3 ng/mL. Compared with patients with 25(OH)D levels <15 ng/mL, those with levels of 15 to 25 ng/mL and >25 ng/mL exhibited greater reductions in HbA1c [β = −0.083, 95% CI (−0.154 to −0.013), p = 0.020; and β = −0.096, 95% CI (−0.173 to −0.017), p = 0.016, respectively] and BMI [β = −1.02, 95% CI (−1.46 to −0.58); and β = −1.29, 95% CI (−1.77 to −0.80); both p < 0.0001]. No association was found with lipid profile.

Conclusion

Higher baseline 25(OH)D levels are independently associated with improved glycemic and weight loss responses to semaglutide in individuals with T2D. Prospective trials are warranted to explore whether vitamin D supplementation may potentiate semaglutide’s metabolic effects.

Publication and source details

Original title: Baseline vitamin D status is associated with glycemic and weight loss outcomes in patients with type 2 diabetes treated with semaglutide

Ariel Israel; Mahmud Moed; Hala Abo Fanne; Aviv Kedem; Mahmoud Odeh; Kareem Abu Rashed; Tayser Marzook; Isis Abumouch; Rami Abu Fanne

Frontiers in Nutrition · 2026

* Correspondence: Rami Abu Fanne, ramia@hymc.gov.ilCopyright © 2026 Israel, Moed, Abo Fanne, Kedem, Odeh, Rashed, Marzook, Abumouch and Fanne.2026Israel, Moed, Abo Fanne, Kedem, Odeh, Rashed, Marzook, Abumouch and Fannehttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was not received for this work and/or its publication.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T10:42:41.475870+00:00

DOI: 10.3389/fnut.2026.1833045 · PMC13159200